Week In Review: 3SBio Inc. Snags Global Rights To mAb For Arthritis

China's 3SBio acquired ex-China rights (it already owned China rights) for an anti-TNF mAb aimed at rheumatoid arthritis from Apexigen of San Francisco; Materialise of Belgium opened a multidisciplinary 3D printing center in Beijing's Fuwai Hospital to aid in difficult cardiovascular surgeries; Ascletis, a Hangzhou-US pharma, said China and Taiwan accepted a CTA to test its dual-drug, interferon-free regimen for hepatitis C, a first in China; BeiGene of Beijing was granted FDA approval to start US clinical trials of a BTK inhibitor for B-cell malignancies; Taiwan's PharmaEngine reported its pancreatic cancer drug candidate was granted priority review in the US and earned a $11 million milestone for a European filing; and SGS Life Science Services expanded its microbiology testing lab in Shanghai.

Help employers find you! Check out all the jobs and post your resume.